AB0388 COMPARATIVE EFFECTIVENESS OF RITUXIMAB, TOCILIZUMAB AND TNFI BIOLOGICS IN RHEUMATOID ARTHRITIS PATIENTS. INFLUENCE OF CLINICAL AND INFLAMMATORY PROFILES
C. López-Pedrera(Instituto Maimónides de Investigación Biomédica de Córdoba), Eduardo Collantes‐Estévez(Hospital Universitario Reina Sofía), P. S. Laura(Instituto Maimónides de Investigación Biomédica de Córdoba), D. Ruiz-Montesinos(Hospital Universitario Virgen Macarena), Alejandro Ibáñez‐Costa(Instituto de Salud Carlos III), R. Ortega Castro(Instituto Maimónides de Investigación Biomédica de Córdoba), Carmen María Romero-Barco(Instituto de Investigación Biomédica de Málaga), C. Rodríguez-Escalera(Complejo Hospitalario de Jaén), M. Á. Aguirre(Instituto Maimónides de Investigación Biomédica de Córdoba), Natalia Mena‐Vázquez(Hospital Regional Universitario de Málaga), I. Arias de la Rosa(Instituto Maimónides de Investigación Biomédica de Córdoba), M. Luque-Tévar(Instituto Maimónides de Investigación Biomédica de Córdoba), Ma Dolores Toledo-Coello(Hospital Jerez Puerta del Sur), Alejandro Escudero‐Contreras(Instituto Maimónides de Investigación Biomédica de Córdoba), A. M. Patiño-Trives(Instituto Maimónides de Investigación Biomédica de Córdoba), Julia Uceda(Hospital Universitario de Valme), N. Barbarroja Puerto(Instituto Maimónides de Investigación Biomédica de Córdoba)
Cited by 0
Related Papers
Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome
|Journal of Thrombosis and Haemostasis|2011|120
Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas
|Cancer Letters|2015|91
Ghrelin gene products, receptors, and GOAT enzyme: biological and pathophysiological insight
|Journal of Endocrinology|2013|88
A Cellular and Molecular Basis for the Selective Desmopressin-Induced ACTH Release in Cushing Disease Patients: Key Role of AVPR1b Receptor and Potential Therapeutic Implications
|The Journal of Clinical Endocrinology & Metabolism|2013|81
Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro
|Journal of Endocrinology|2016|74